Amiko
Financials
Estimates*
EUR | 2022 |
---|---|
Revenues | 2.0m |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Seed | ||
* | N/A | Early VC | |
Total Funding | - |
Recent News about Amiko
EditAmiko is a global provider of hardware-enabled, AI-powered digital medicines, primarily serving the healthcare sector. The company's flagship product, Respiro, is a digital medicine platform designed to upgrade respiratory care. Respiro integrates proprietary sensing technology, cognitive computing, and elegant digital experiences to deliver better health outcomes for patients with respiratory conditions. The platform works by attaching sensors to existing inhalers or using inhalers with built-in sensors, which then collect and analyze data to provide actionable insights. These insights help patients manage their conditions more effectively and allow healthcare providers to monitor and adjust treatments in real-time. Amiko operates in the digital health market, focusing on respiratory care, and generates revenue through partnerships with healthcare providers and direct sales of its Respiro-enabled inhalers and sensors. The business model is based on a combination of hardware sales and subscription-based services for data analytics and digital health management.
Keywords: digital medicine, respiratory care, AI-powered, connected inhalers, data analytics, healthcare, cognitive computing, sensing technology, patient management, digital health.